Aoxing Pharmaceutical Company, Inc. (AOXG)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Aoxing Pharmaceutical Company, Inc. (AOXG) with AI Score 49/100 (Weak). Aoxing Pharmaceutical Company, Inc. focuses on the research, development, manufacture, and distribution of narcotic, pain-management, and addiction treatment pharmaceutical products in China. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026Aoxing Pharmaceutical Company, Inc. (AOXG) Healthcare & Pipeline Overview
Aoxing Pharmaceutical Company, Inc. is a specialty pharmaceutical company based in China, focusing on narcotic, pain-management, and addiction treatment products, including both herbal and synthetic drugs. With a negative P/E ratio and high gross margin, the company navigates a competitive landscape while developing new pain and addiction treatments.
Investment Thesis
Aoxing Pharmaceutical Company, Inc. presents a high-risk, high-reward investment profile. The company's focus on the Chinese market for pain management and addiction treatment offers potential growth, especially with its pipeline of drugs like Oxycodone/Acetaminophen and Buprenorphine/Naloxone. However, the company's negative P/E ratio of -183.91 and a negative profit margin of -79.5% raise concerns about its financial stability. Successful navigation of clinical trials and regulatory approvals for its pipeline drugs are key catalysts. Investors should closely monitor the company's progress in these areas, as well as its ability to improve profitability and manage its high beta of -59.16.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $0.00B indicates a micro-cap company with limited resources and higher volatility.
- P/E Ratio of -183.91 reflects the company's current unprofitability, requiring careful evaluation of future earnings potential.
- Gross Margin of 88.1% suggests strong pricing power on existing products, but this needs to translate into overall profitability.
- Beta of -59.16 indicates an inverse correlation with the market, which is unusual and may be due to the stock's illiquidity or unique business model.
- Focus on narcotic, pain-management, and addiction treatment pharmaceutical products in China, a market with significant unmet needs and growth potential.
Competitors & Peers
Strengths
- Specialized focus on pain management and addiction treatment.
- Established manufacturing capabilities in China.
- Pipeline of drugs in development.
- Existing distribution network within China.
Weaknesses
- Negative profitability and high debt levels.
- Reliance on a single geographic market (China).
- Limited financial resources for R&D and marketing.
- OTC Other tier indicates higher risk.
Catalysts
- Upcoming: Regulatory approval and commercialization of Oxycodone and Acetaminophen tablets and capsules for pain management.
- Upcoming: Positive results from Phase III clinical trials for Buprenorphine/Naloxone in treating opioid dependence.
- Ongoing: Expansion of distribution network within China to reach more patients.
- Ongoing: Increased government support for domestic pharmaceutical companies in China.
- Ongoing: Growing demand for pain management and addiction treatment products in China.
Risks
- Potential: Failure to obtain regulatory approvals for pipeline drugs.
- Potential: Intense competition from established pharmaceutical companies.
- Ongoing: Pricing pressures from generic drug manufacturers.
- Ongoing: Dependence on the Chinese market and regulatory environment.
- Potential: Product liability claims and lawsuits.
Growth Opportunities
- Expansion of Product Portfolio: Aoxing's pipeline of drugs in development, including Oxycodone/Acetaminophen and Buprenorphine/Naloxone, represents a significant growth opportunity. Successful completion of clinical trials and regulatory approvals could lead to new revenue streams and market share gains. The market for pain management and addiction treatment is substantial, with the global market estimated to reach billions of dollars in the coming years. Timeline: 2-5 years for regulatory approvals.
- Geographic Expansion within China: While Aoxing primarily operates in China, there is potential to expand its geographic reach within the country. Targeting specific regions with high demand for pain management and addiction treatment products could drive revenue growth. This expansion could involve establishing new distribution channels and partnerships. Timeline: 1-3 years.
- Strategic Partnerships and Acquisitions: Aoxing could pursue strategic partnerships or acquisitions to expand its product portfolio, geographic reach, or technological capabilities. Collaborating with other pharmaceutical companies or research institutions could accelerate the development and commercialization of new drugs. Timeline: Ongoing.
- Increased Investment in Research and Development: Aoxing could increase its investment in research and development to discover and develop novel drugs for pain management and addiction treatment. This could involve conducting preclinical and clinical studies, as well as collaborating with academic institutions and research organizations. Timeline: Long-term, 5+ years.
- Leveraging Government Support for Domestic Pharmaceutical Companies: The Chinese government is actively supporting the growth of domestic pharmaceutical companies through various policies and initiatives. Aoxing can leverage these policies to access funding, streamline regulatory approvals, and gain a competitive advantage. Timeline: Ongoing.
Opportunities
- Expanding into new geographic markets.
- Developing new drug formulations and delivery methods.
- Partnering with other pharmaceutical companies.
- Leveraging government support for domestic pharmaceutical companies.
Threats
- Intense competition from established pharmaceutical companies.
- Stringent regulatory requirements.
- Pricing pressures from generic drug manufacturers.
- Potential product liability claims.
Competitive Advantages
- Proprietary drug formulations and intellectual property.
- Established distribution network within China.
- Expertise in developing and manufacturing narcotic and pain-relief medications.
- Regulatory approvals for its existing products.
About AOXG
Aoxing Pharmaceutical Company, Inc., headquartered in Shijiazhuang, China, is a specialty pharmaceutical company dedicated to the research, development, manufacture, and distribution of pharmaceutical products. The company primarily operates in the People's Republic of China, focusing on narcotic, pain-management, and addiction treatment medications. Aoxing’s product portfolio includes Zhongtong'an, a herbal capsule designed for oral and dental pain relief, and Yiqi Qiangshen Granule, an over-the-counter herbal supplement aimed at tonifying qi, empowering the body, and promoting blood circulation. Additionally, the company manufactures Tilidine hydrochloride, a synthetic narcotic analgesic tablet used for moderate to severe pain relief. Further expanding their offerings, Aoxing has several products in development, including Oxycodone and Acetaminophen tablets and capsules, which have completed clinical trials for treating acute and chronic pain. They are also developing Buprenorphine/Naloxone, a sublingual tablet for opioid dependence treatment, which has completed Phase II clinical trials, and Tilidine/Naloxone, a compound capsule in Phase II clinical trials for acute and chronic pain management. Originally known as China Aoxing Pharmaceutical Company, Inc., the company rebranded to Aoxing Pharmaceutical Company, Inc. in March 2010, solidifying its commitment to advancing pharmaceutical solutions.
What They Do
- Researches and develops pharmaceutical products focused on pain management, addiction treatment, and related areas.
- Manufactures narcotic and non-narcotic pain relief medications.
- Produces herbal extraction products for pain relief and general health improvement.
- Distributes its pharmaceutical products primarily within the People's Republic of China.
- Conducts clinical trials for new drug candidates, including treatments for opioid dependence.
- Markets both prescription and over-the-counter (OTC) medications.
Business Model
- Develops and manufactures pharmaceutical products.
- Sells prescription and OTC medications through distributors and directly to healthcare providers.
- Generates revenue from the sale of its proprietary drug formulations.
- Invests in research and development to create new products and improve existing ones.
Industry Context
Aoxing Pharmaceutical Company, Inc. operates within the specialty and generic drug manufacturing industry, a sector characterized by intense competition and stringent regulatory oversight. The Chinese pharmaceutical market is experiencing rapid growth, driven by an aging population and increasing healthcare spending. However, domestic companies face challenges from international players and evolving regulatory standards. Aoxing's focus on pain management and addiction treatment positions it in a niche market with specific needs, but also heightened regulatory scrutiny. Competitors like AREVF and CWWBF also operate in this space.
Key Customers
- Hospitals and clinics throughout China.
- Pharmacies and drug stores.
- Patients seeking pain relief and addiction treatment.
- Healthcare providers prescribing medications.
Financials
Chart & Info
Aoxing Pharmaceutical Company, Inc. (AOXG) stock price: Price data unavailable
Latest News
No recent news available for AOXG.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for AOXG.
Price Targets
Wall Street price target analysis for AOXG.
MoonshotScore
What does this score mean?
The MoonshotScore rates AOXG's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Zhenjiang Yue
CEO
Zhenjiang Yue serves as the CEO of Aoxing Pharmaceutical Company, Inc. He is responsible for overseeing the company's overall strategy, operations, and financial performance. His leadership is crucial in guiding Aoxing through the complex regulatory landscape and competitive market in China. He manages a workforce of 346 employees, focusing on research, development, and manufacturing of pharmaceutical products.
Track Record: Under Zhenjiang Yue's leadership, Aoxing Pharmaceutical Company has focused on developing and commercializing pain management and addiction treatment products. Key milestones include advancing clinical trials for pipeline drugs such as Oxycodone/Acetaminophen and Buprenorphine/Naloxone. The company has also maintained its presence in the Chinese pharmaceutical market despite financial challenges.
AOXG OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Aoxing Pharmaceutical Company, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, making it difficult for investors to assess their financial health and viability. Investing in OTC Other stocks carries significantly higher risk compared to stocks listed on major exchanges like the NYSE or NASDAQ due to the lack of regulatory oversight and transparency.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Higher risk of fraud and manipulation.
- Potential for delisting or suspension of trading.
- Limited regulatory oversight.
- Verify the company's registration and legal status.
- Obtain and review any available financial statements.
- Assess the company's business model and competitive landscape.
- Evaluate the management team's experience and track record.
- Understand the risks associated with investing in OTC Other stocks.
- Consult with a qualified financial advisor.
- Check for any regulatory actions or legal disputes.
- Existence of a physical headquarters and operational facilities.
- Presence of a functional website and contact information.
- Patents or intellectual property related to its products.
- Partnerships with reputable organizations or institutions.
- Active engagement with investors and the public.
What Investors Ask About Aoxing Pharmaceutical Company, Inc. (AOXG)
What does Aoxing Pharmaceutical Company, Inc. do?
Aoxing Pharmaceutical Company, Inc. is a specialty pharmaceutical company focused on the research, development, manufacture, and distribution of narcotic, pain-management, and addiction treatment pharmaceutical products, primarily in China. Its key products include Zhongtong'an capsules for oral pain, Yiqi Qiangshen Granule for general health, and Tilidine hydrochloride tablets for acute and chronic pain. The company is also developing new treatments for opioid dependence and pain management.
What do analysts say about AOXG stock?
As of 2026-03-17, there is no readily available analyst coverage or consensus for Aoxing Pharmaceutical Company, Inc. due to its OTC Other listing and limited financial disclosure. The company's negative P/E ratio and lack of profitability make valuation challenging. Investors should conduct thorough due diligence and assess the company's growth potential and risk factors independently. The stock's high beta suggests significant volatility.
What are the main risks for AOXG?
Aoxing Pharmaceutical Company, Inc. faces several key risks, including regulatory hurdles in China, intense competition from both domestic and international pharmaceutical companies, and the potential for product liability claims. The company's financial instability, as indicated by its negative P/E ratio and profit margin, also poses a significant risk. Additionally, its OTC Other listing implies limited transparency and liquidity, increasing the risk of price manipulation and delisting.
What are the key factors to evaluate for AOXG?
Aoxing Pharmaceutical Company, Inc. (AOXG) currently holds an AI score of 49/100, indicating low score. Key strength: Specialized focus on pain management and addiction treatment.. Primary risk to monitor: Potential: Failure to obtain regulatory approvals for pipeline drugs.. This is not financial advice.
How frequently does AOXG data refresh on this page?
AOXG prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven AOXG's recent stock price performance?
Recent price movement in Aoxing Pharmaceutical Company, Inc. (AOXG) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Specialized focus on pain management and addiction treatment.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider AOXG overvalued or undervalued right now?
Determining whether Aoxing Pharmaceutical Company, Inc. (AOXG) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying AOXG?
Before investing in Aoxing Pharmaceutical Company, Inc. (AOXG), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of 2026-03-17.
- OTC Other stocks carry significant risks and require thorough due diligence.
- Financial data may be limited or unaudited.